drugset / Trial / NCT03386474
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
Non-randomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this extension study was to assess the safety and efficacy of the new formulation of brolucizumab 6 mg ophthalmic solution when given to the same patients who received brolucizumab in the core trial CRTH258A2301 (also known as CRTH258-C002). The medical condition treated in the core and extension trials was neo-vascular age-related macular degeneration (nAMD).
Timeline
- Start
- 2018-01-15
- Primary completion
- 2018-09-06
- Completion
- 2018-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brolucizumab | Other / unclassified | 6 mg | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |